AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26987056 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric conventional formula (CF, providing 2.1g maltodextrin/100mL)
Number of subjects: 50
Study 26987056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention follow‐on formula (IF)
Number of subjects: 50
Study 26987056 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric conventional formula (CF)
Number of subjects: 50
Study 26987056 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulae
Number of subjects: 50
Study 24104542 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal frequency breathing with fins (F)
Number of subjects: 15
Study 24104542 — intervention group
Group type: COMPARATOR
Intervention: Normal frequency breathing without fins (S)
Number of subjects: 15
Study 24104542 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete apnea with fins (FAp)
Number of subjects: 15
Study 24104542 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete apnea without fins (SAp)
Number of subjects: 15
Study 24104542 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva dehydroepiandrosterone
Number of subjects: 15
Study 24104542 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva cortisol and testosterone
Number of subjects: 15
Study 21553010 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0
Study 19624401 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional care interventions (specific interventions not detailed)
Number of subjects: 0
Study 19624401 — intervention group
Group type: COMPARATOR
Intervention: Nutritional screening
Number of subjects: 0
Study 18004127 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg)
Number of subjects: 12
Study 18004127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15209786 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashlamp-pulsed dye laser treatment
Number of subjects: 0
Study 15209786 — intervention group
Group type: COMPARATOR
Intervention: Different flashlamp-pulsed dye laser settings
Number of subjects: 0
Study 11438914 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 15 mg/kg/day orally in 2 divided doses for 7 days
Number of subjects: 51
Study 11438914 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol, 50 mg/kg/day orally in 4 divided doses for 7 days
Number of subjects: 51
Study 9580263 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine triphosphate (ATP) - bolus injections of 3, 6 and 9 mg/5 min
Number of subjects: 30
Study 9580263 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol - bolus injections of 2, 4 and 6 micrograms/5 min
Number of subjects: 30
Study 9580263 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects) - adenosine in the upright position
Number of subjects: 30
Study 7851367 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (E)
Number of subjects: 62
Study 7851367 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group (NE)
Number of subjects: 62
Study 3132866 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.8 mg/70 kg)
Number of subjects: 20
Study 3132866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31975352 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 974
Study 31975352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 974
Study 30450689 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastiha (2.8 g/day)
Number of subjects: 60
Study 30450689 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28586537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vericiguat 10 mg once daily
Number of subjects: 477
Study 28586537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 477
Study 27032739 — intervention group
Group type: EXPERIMENTAL
Intervention: IVPCA with fentanyl
Number of subjects: 37
Study 27032739 — intervention group
Group type: COMPARATOR
Intervention: PCEA with bupivacaine and fentanyl
Number of subjects: 37
Study 24559855 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid milk (3g phospholipids, 0.75g sphingomyelin)
Number of subjects: 39
Study 24559855 — intervention group
Group type: COMPARATOR
Intervention: Control milk (normal whole milk)
Number of subjects: 39
Study 22588692 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-field surgical carpal tunnel release followed by longitudinal epineurotomy of the nerve (test)
Number of subjects: 50
Study 22588692 — intervention group
Group type: COMPARATOR
Intervention: Open-field release without epineurotomy (control)
Number of subjects: 50
Study 19509121 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 years of bisphosphonate treatment
Number of subjects: 2000
Study 19509121 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 years of bisphosphonate treatment
Number of subjects: 2000
Study 19509121 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 to 5000 participants per arm
Number of subjects: 2000
Study 17215185 — intervention group
Group type: EXPERIMENTAL
Intervention: 200,000 IU of Vitamin A
Number of subjects: 613
Study 17215185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 14712422 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids and cyclosporine (group 1)
Number of subjects: 57
Study 14712422 — intervention group
Group type: COMPARATOR
Intervention: Steroids and chlorambucil (group 2)
Number of subjects: 57
Study 12136499 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention (short workbook on appearance damaging effects of indoor tanning)
Number of subjects: 147
Study 12136499 — intervention group
Group type: EXPERIMENTAL
Intervention: Appearance-focused intervention
Number of subjects: 147
Study 12136499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 147
Study 9572758 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention clinics run by nurses in general practice
Number of subjects: 1173
Study 9207310 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2 intravenously once a week for 3 weeks (days 1, 8, and 15) followed by a 1-week rest period.
Number of subjects: 117
Study 9207310 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 intravenously on day 1 of each 28-day cycle in combination with etoposide 100 mg/m2 on days 1, 2, and 3.
Number of subjects: 117
Study 1742909 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg/kg i.v.)
Number of subjects: 15
Study 1742909 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 15
Study 1742909 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 6890840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicyclic acid (ASA)
Number of subjects: 0
Study 6890840 — intervention group
Group type: EXPERIMENTAL
Intervention: Carprofen
Number of subjects: 0
Study 6890840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31999615 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 61
Study 31999615 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study 30782923 — intervention group
Group type: EXPERIMENTAL
Intervention: Advisory board and consultancies COI for gout review
Number of subjects: 749
Study 30782923 — intervention group
Group type: COMPARATOR
Intervention: No COI for gout review
Number of subjects: 749
Study 30782923 — intervention group
Group type: EXPERIMENTAL
Intervention: Gout review
Number of subjects: 749
Study 30782923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyspepsia review
Number of subjects: 749
Study 28142146 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical staging (arm A)
Number of subjects: 234
Study 28142146 — intervention group
Group type: COMPARATOR
Intervention: Clinical staging and primary chemoradiation (arm B)
Number of subjects: 234
Study 25344881 — intervention group
Group type: EXPERIMENTAL
Intervention: SCPB (Superficial Cervical Plexus Block) with 10 ml 0.25% bupivacaine each side
Number of subjects: 50
Study 25344881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SCPB)
Number of subjects: 50
Study 25344881 — intervention group
Group type: EXPERIMENTAL
Intervention: SCPB
Number of subjects: 50
Study 25344881 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 25344881 — intervention group
Group type: EXPERIMENTAL
Intervention: SCPB and Control groups
Number of subjects: 50
Study 26404199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 270 mg loading dose
Number of subjects: 52
Study 26404199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 180 mg loading dose
Number of subjects: 52
Study 26404199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 360 mg loading dose
Number of subjects: 52
Study 26404199 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor 180 mg, 270 mg, 360 mg loading doses
Number of subjects: 52
Study 23722481 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated 5-hour Energy shot
Number of subjects: 20
Study 23722481 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated 5-hour Energy shot
Number of subjects: 20
Study 22066355 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing INR using CoaguChek (Roche) or INRatio (Hemosense) system (Group 2)
Number of subjects: 206
Study 22066355 — intervention group
Group type: COMPARATOR
Intervention: Conventional management with laboratory INR monitoring (Group 1)
Number of subjects: 206
Study 22066355 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-testing INR (Group 2)
Number of subjects: 206
Study 22066355 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (Group 1)
Number of subjects: 206
Study 19955065 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair (n = 25)
Number of subjects: 37
Study 19955065 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing of defective margins (n = 12)
Number of subjects: 37
Study 19955065 — intervention group
Group type: EXPERIMENTAL
Intervention: Refinishing (n = 19)
Number of subjects: 37
Study 19955065 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement (n = 16)
Number of subjects: 37
Study 19955065 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 16)
Number of subjects: 37
Study 16341569 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LGBP)
Number of subjects: 392
Study 16341569 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic adjustable silicone gastric banding (LASGB)
Number of subjects: 392
Study 16341569 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LGBP and LASGB
Number of subjects: 392
Study 15486842 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine in the home
Number of subjects: 0
Study 12575370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongyu No. I (TY‐1)
Number of subjects: 62
Study 12575370 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (control group)
Number of subjects: 62
Study 10223211 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin (200 mg/m2)
Number of subjects: 100
Study 10223211 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin (500 mg/m2)
Number of subjects: 100
Study 10223211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin (3 mg/m2)
Number of subjects: 100
Study 10223211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambdacyhalothrin (15 mg/m2)
Number of subjects: 100
Study 10223211 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 100
Study 8272303 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose monophasic pill
Number of subjects: 40
Study 8272303 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose monophasic pill
Number of subjects: 40
Study 8272303 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiphasic pill
Number of subjects: 40
Study 8272303 — intervention group
Group type: COMPARATOR
Intervention: Nonsteroidal contraception
Number of subjects: 40
Study 2679084 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5 to 10 mg once every afternoon (stratum I)
Number of subjects: 290
Study 2679084 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 to 20 mg once every afternoon (stratum II)
Number of subjects: 290
Study 2679084 — intervention group
Group type: COMPARATOR
Intervention: Gemfibrozil 600 mg twice daily (both strata)
Number of subjects: 290
Study 2679084 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 5 to 10 mg once every afternoon and gemfibrozil 600 mg twice daily
Number of subjects: 290
Study 2679084 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 to 20 mg once every afternoon
Number of subjects: 290
Study 2679084 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 290
Study 1069556 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-cultured cell mixtures
Number of subjects: 62
Study 1069556 — intervention group
Group type: COMPARATOR
Intervention: BCG alone
Number of subjects: 62
Study 31937617 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 46
Study 23292649 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS assisted CAS
Number of subjects: 60
Study 23292649 — intervention group
Group type: COMPARATOR
Intervention: CAS using angiography as the unique diagnostic tool
Number of subjects: 60
Study 28629272 — intervention group
Group type: EXPERIMENTAL
Intervention: Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) + Treatment as Usual (TAU)
Number of subjects: 12
Study 28629272 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 12
Study 26254792 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*wt/*10 genotype
Number of subjects: 62
Study 26254792 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10 genotype
Number of subjects: 62
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalline lysine (CLys)
Number of subjects: 112
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized ileal digestible (SID) Lys from SBM
Number of subjects: 112
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Lys concentration increased
Number of subjects: 112
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigs fed individually
Number of subjects: 112
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigs fed CLys diets
Number of subjects: 112
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilts
Number of subjects: 112
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Pigs fed individually with CLys
Number of subjects: 112
Study 23881680 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrows fed individually
Number of subjects: 112
Study 21764540 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 200
Study 21764540 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 200
Study 19906518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral GSH levels in myalgic encephalomyelitis patients
Number of subjects: 26
Study 19906518 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (age- and gender-matched)
Number of subjects: 26
Study 17029618 — intervention group
Group type: COMPARATOR
Intervention: 40 tablets (60 g) of NaP
Number of subjects: 816
Study 17029618 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-NaP 40 tablets (60 g)
Number of subjects: 816
Study 17029618 — intervention group
Group type: EXPERIMENTAL
Intervention: RF-NaP 32 tablets (48 g)
Number of subjects: 816
Study 17029618 — intervention group
Group type: COMPARATOR
Intervention: NaP
Number of subjects: 816
Study 12767425 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (L-T(4)) replacement therapy for 6 months
Number of subjects: 10
Study 12767425 — intervention group
Group type: COMPARATOR
Intervention: Control group of 14 euthyroid patients (52.5 +/- 10 years); thyroid-stimulating hormone 2.5 +/- 1.2 microUI/ml
Number of subjects: 10
Study 11144687 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trials in gynecologic oncology
Number of subjects: 0
Study 11144687 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 0
Study 11144687 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol review process
Number of subjects: 0
Study 11144687 — intervention group
Group type: EXPERIMENTAL
Intervention: Publication of trial results
Number of subjects: 0
Study 11144687 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim analyses
Number of subjects: 0
Study 11144687 — intervention group
Group type: EXPERIMENTAL
Intervention: International cooperation in trials
Number of subjects: 0
Study 9425505 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist and calcium, with or without nasal salmon calcitonin
Number of subjects: 40
Study 8917031 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine gluconate, 0.025% benzalkonium chloride, and 4% benzyl alcohol
Number of subjects: 0
Study 8917031 — intervention group
Group type: COMPARATOR
Intervention: 10% povidone iodine
Number of subjects: 0
Study 2808197 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate 666 mg tid
Number of subjects: 162
Study 2808197 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base 500 mg qid
Number of subjects: 162
Study 2808197 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate 400 mg qid
Number of subjects: 162
Study 4604478 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell Inaba vaccine (2 annual injections)
Number of subjects: 45000
Study 4604478 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified Inaba vaccine (1 injection)
Number of subjects: 45000
Study 4604478 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-cell Ogawa vaccine (2 annual injections)
Number of subjects: 45000
Study 4604478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ogawa vaccine
Number of subjects: 45000
Study 31039755 — intervention group
Group type: EXPERIMENTAL
Intervention: One‐staged hybrid operation
Number of subjects: 0
Study 31039755 — intervention group
Group type: COMPARATOR
Intervention: Traditional operation
Number of subjects: 0
Study 29240757 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 session integrated cognitive behavioral therapy and HIV prevention intervention (n = 162)
Number of subjects: 315
Study 29240757 — intervention group
Group type: COMPARATOR
Intervention: Single session control (n = 153)
Number of subjects: 315
Study 24604664 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic inversion time (dynamic‐TI)
Number of subjects: 17
Study 24604664 — intervention group
Group type: COMPARATOR
Intervention: Without dynamic inversion time
Number of subjects: 17
Study 23428257 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (TSD)
Number of subjects: 16
Study 23428257 — intervention group
Group type: COMPARATOR
Intervention: Sleep condition
Number of subjects: 16
Study 21494548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive phase therapy for tuberculosis in African patients
Number of subjects: 328
Study 21494548 — intervention group
Group type: COMPARATOR
Intervention: Intensive phase therapy for tuberculosis in non-African patients
Number of subjects: 328
Study 21494548 — intervention group
Group type: EXPERIMENTAL
Intervention: African patients with the least disease severity
Number of subjects: 328
Study 21494548 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV infection, smoking, and diabetes
Number of subjects: 328
Study 21494548 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory processing and culture procedures
Number of subjects: 328
Study 19221370 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous esomeprazole (80 mg bolus followed by 8 mg/h infusion for 72 hours)
Number of subjects: 767
Study 16530503 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 8
Number of subjects: 175
Study 16530503 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 12
Number of subjects: 175
Study 16530503 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2b monotherapy (1.5 microg/kg per week) started at week 20
Number of subjects: 175
Study 16530503 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with peginterferon alfa‐2b
Number of subjects: 175
Study 15108656 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone maintenance treatment (MMT)
Number of subjects: 0
Study 11128923 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen barrier
Number of subjects: 48
Study 11128923 — intervention group
Group type: COMPARATOR
Intervention: ePTFE barrier
Number of subjects: 48
Study 11128923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both barriers
Number of subjects: 48
Study 9301631 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin at night
Number of subjects: 22
Study 9301631 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin twice a day
Number of subjects: 22
Study 8408501 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen and progestin supplementation
Number of subjects: 30
Study 8408501 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 30
Study 3895810 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 0
Study 3895810 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium
Number of subjects: 0
Study 3895810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30257125 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc‐/copper‐containing welding fumes (2.5 mg/m3)
Number of subjects: 15
Study 30257125 — intervention group
Group type: COMPARATOR
Intervention: Ambient air control
Number of subjects: 15
Study 26562003 — intervention group
Group type: EXPERIMENTAL
Intervention: Head Massage Therapy (HMT)
Number of subjects: 10
Study 26562003 — intervention group
Group type: COMPARATOR
Intervention: Control (no HMT)
Number of subjects: 10
Study 25267153 — intervention group
Group type: EXPERIMENTAL
Intervention: Advax 5mg
Number of subjects: 16
Study 25267153 — intervention group
Group type: EXPERIMENTAL
Intervention: Advax 10mg
Number of subjects: 16